Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

• Drug: dacomitinib fasted
  
  Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
• Drug: dacomitinib fed
  
  Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
• Drug: dacomitinib+antacid
  
  Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole

• Experimental: Fasted
  
  Dacomitinib administered under fasted conditions
  Intervention: Drug: dacomitinib fasted
• Experimental: Fed
  
  Dacomitinib administered under fed conditions
  Intervention: Drug: dacomitinib fed
• Experimental: Antacid
  
  Dacomitinib administered under antacid treatment
  Intervention: Drug: dacomitinib+antacid

Inclusion Criteria:

• Healthy subjects including males between the ages of 18 and 55 years. Females of non childbearing potential .
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
• An informed consent document signed and dated by the subject.

Exclusion Criteria:

• Any condition possibly affecting drug absorption (eg, gastrectomy).
• A positive urine drug screen.
• Treatment with an investigational drug within 30 days (or as determined by the local requirement) or the appropriate time based on the elimination characteristics of the study medication.